Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delipidated deglycolipidated Mycobacterium vaccae
- Development stage
- Unknown
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Delipidated deglycolipidated Mycobacterium vaccae is a modified preparation of the non-pathogenic environmental bacterium *Mycobacterium vaccae*, in which lipids and glycolipids have been removed through chemical extraction processes[3][4]. This formulation is designed to reduce reactogenicity while retaining immunomodulatory properties. It has been investigated as an immunotherapeutic agent for immune-mediated diseases such as psoriasis and psoriatic arthritis[3][5], and has also been studied in asthma[1][2]. The mechanism of action involves modulation of immune responses—potentially by shifting T cell activity or acting as an adjuvant to enhance antigen-specific cytotoxic T lymphocyte (CTL) responses[4]. The product known as "PVAC" is an investigational new drug registered with the US FDA for clinical trials in psoriasis[3].
- Brand names
- PVAC
- Other names
- delipidated deglycolipidated M. vaccaeDD-M. vaccaeDDMVPVAC
Beyond the preview
Go deeper on delipidated deglycolipidated Mycobacterium vaccae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delipidated deglycolipidated Mycobacterium vaccae.